Zoetis (NYSE:ZTS – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Zoetis to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.
Valuation & Earnings
This table compares Zoetis and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Zoetis | $9.47 billion | $2.67 billion | 14.23 |
| Zoetis Competitors | $3.55 billion | $3.17 billion | 562.76 |
Zoetis has higher revenue, but lower earnings than its peers. Zoetis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Zoetis and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zoetis | 26.15% | 85.90% | 18.39% |
| Zoetis Competitors | -2,398.26% | -203.62% | -15.08% |
Dividends
Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.5%. Zoetis pays out 36.1% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend. Zoetis has increased its dividend for 14 consecutive years.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Zoetis and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zoetis | 1 | 12 | 8 | 0 | 2.33 |
| Zoetis Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
Zoetis currently has a consensus price target of $101.25, suggesting a potential upside of 21.04%. As a group, “Pharmaceuticals” companies have a potential upside of 24.70%. Given Zoetis’ peers stronger consensus rating and higher possible upside, analysts clearly believe Zoetis has less favorable growth aspects than its peers.
Volatility & Risk
Zoetis has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Zoetis’ peers have a beta of -0.04, suggesting that their average stock price is 104% less volatile than the S&P 500.
Institutional & Insider Ownership
92.8% of Zoetis shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Zoetis peers beat Zoetis on 8 of the 15 factors compared.
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
